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Abstract
The atrial natriuretic factor (ANF) gene is initially expressed throughout the myocardial layer of the heart, but during subsequent
development, expression becomes limited to the atrial chambers. Mouse knockout and mammalian cell culture studies have shown that the
ANF gene is regulated by combinatorial interactions between Nkx2-5, GATA-4, Tbx5, and SRF; however, the molecular mechanisms
leading to chamber-specific expression are currently unknown. We have isolated the Xenopus ANF promoter in order to examine the
temporal and spatial regulation of the ANF gene in vivo using transgenic embryos. The mammalian and Xenopus ANF promoters show
remarkable sequence similarity, including an Nkx2-5 binding site (NKE), two GATA sites, a T-box binding site (TBE), and two SRF
binding sites (SREs). Our transgenic studies show that mutation of either SRE, the TBE or the distal GATA element, strongly reduces
expression from the ANF promoter. However, mutations of the NKE, the proximal GATA, or both elements together, result in relatively
minor reductions in transgene expression within the myocardium. Surprisingly, mutation of these elements results in ectopic ANF promoter
activity in the kidneys, facial muscles, and aortic arch artery-associated muscles, and causes persistent expression in the ventricle and
outflow tract of the heart. We propose that the NKE and proximal GATA elements serve as crucial binding sites for assembly of a repressor
complex that is required for atrial-specific expression of the ANF gene.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
The morphological events involved in formation of the
vertebrate heart have been well described, but much less is
understood about the molecular mechanisms regulating
gene expression during cardiogenesis. One class of tran-
scription factors that are known to be important for heart
development are homeodomain proteins of the tinman fam-
ily. In Drosophila, absence of tinman function completely
abolishes formation of the dorsal vessel, the insect equiva-
lent of the vertebrate heart (Bodmer, 1993; Azpiazu and
Frasch, 1993). In vertebrates, a small family of tinman-
related genes are expressed in the developing heart. The
best-characterized member of the vertebrate tinman family
is Nkx2-5 (also called Csx), which is among the very ear-
liest markers of the cardiac lineage (Harvey, 1996; Komuro
and Izumo, 1993). Nkx2-5 continues to be expressed
throughout the myocardial layer during subsequent heart
development and in the adult organ. Mice in which Nkx2-5
function has been ablated die at approximately E9.5 due to
cardiac insufficiency (Lyons et al., 1995; Tanaka et al.,
1999). Although a linear heart tube is formed and beating
myocardial tissue is present, the heart tube fails to undergo
the looping and morphogenetic movements associated with
heart maturation. In addition, a number of cardiac genes fail
to be expressed, or are expressed at much reduced levels,
including MLC-2v, CARP, eHand, and atrial natriuretic factor
(ANF) (Lyons et al., 1995; Tanaka et al., 1999). The relevance
of Nkx2-5 function for human cardiac development is evi-
denced by the fact that a number of congenital heart abnor-
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malities, including atrial septal defects, AV conduction defects,
and valvular dismorphogenesis, appear to be associated with
haploinsufficiency of Nkx2-5 expression (Schott et al., 1998;
Rosenthal and Harvey, 1999; Biben et al., 2000).
Nkx2-5 consensus binding sites (NKEs) have been iden-
tified in the promoter regions of a number of cardiac-
expressed genes, including GATA6 (Molkentin et al., 2000),
cardiac  actin (Chen and Schwartz, 1996; Sepulveda et al.,
1998), cardiac troponin I (Bhavsar et al., 2000), and ANF
(Durocher et al., 1996). These genes may therefore be direct
targets of Nkx2-5 regulation. In support of this hypothesis,
in vitro studies using rat cardiomyocytes, CV1 fibroblast
cells, and HeLa cells have shown that Nkx2-5 is able to
activate transcription from the ANF and cardiac  actin
promoters (Durocher et al., 1997; Sepulveda et al., 1998).
Related cell culture studies strongly imply that Nkx2-5
cooperates with other transcription factors to efficiently
activate cardiac gene transcription. For example, examina-
tion of the ANF and cardiac  actin promoters show the
presence of GATA sites and SRF consensus binding sites
(SREs) in close proximity to the Nkx2-5 binding sites.
Cotransfection of both GATA4 and Nkx2-5 into cardiomy-
ocytes, HeLa cells, CV1 cells, or 293 cells results in a
synergistic activation of ANF and cardiac  actin promoter
activity (Durocher and Nemer, 1998; Sepulveda et al., 1998;
Lee et al., 1998). Furthermore, immunoprecipitation exper-
iments suggest a direct physical interaction between the
GATA4 and Nkx2-5 proteins. In an extension of these cell
culture studies, cotransfection of SRF with GATA4 or
Nkx2-5 also shows a synergistic upregulation of cardiac 
actin promoter expression and the highest levels of pro-
moter activity, approximately 200-fold over background,
are observed when all 3 factors are present (Sepulveda et al.,
2002). Overall, these studies strongly suggest that cooper-
ative interactions between the Nkx2-5, GATA4, and SRF
proteins are required for maximal activity of the ANF and
cardiac  actin promoters and probably other cardiac genes.
Transcription factors of the T-box (Tbx) family have also
been shown to play an important role in in cardiogenesis
(Bruneau, 2002). Tbx5 mutations are associated with Holt-
Oram syndrome, a human disease which results in cardiac
and limb defects (Basson et al., 1997, 1999; Li et al., 1997)
and mice heterozygous for Tbx5 display cardiac defects
resembling those of Holt-Oram syndrome (Bruneau et al.,
2001). Furthermore, when Tbx5 is ectopically expressed
throughout the entire heart in chicken embryos, chamber
development proceeds abnormally (Liberatore et al., 2000).
Binding sites for Tbx proteins (TBEs) have been identified
in a number of cardiac-expressed genes, including ANF and
cx40 (Bruneau et al., 2001; Habets et al., 2002). Combina-
torial interactions apparently can occur between Nkx2-5 and
Tbx5 proteins, and synergistic activation of the ANF and
cx40 promoters by these factors has been observed (Bru-
neau et al., 2001). In addition, Tbx2 has been implicated in
repression of ANF expression in the AV canal in transgenic
mice (Habets et al., 2002).
Despite these extensive in vitro studies, the relative im-
portance of the Nkx2-5, GATA4, Tbx5, and SRF proteins
for ANF regulation has not been systematically examined in
transgenic animals. To address this issue, we have isolated
the ANF gene from the frog, Xenopus laevis, and studied its
regulation in transgenic frog embryos. Alignment of the
frog and mammalian promoter sequences shows a remark-
able degree of conservation of transcription factor binding
sites, including two SREs, two GATA sites, a TBE and an
NKE. The presence of these conserved sequence elements
suggests that the transcriptional mechanisms regulating
ANF expression have been highly conserved in evolution-
arily diverse organisms. Our transgenic studies show that
the proximal GATA site and the NKE are relatively unim-
portant for the overall efficiency of expression of the ANF
promoter, but play an essential role in regulating restriction
of ANF expression to the atrium.
Materials and methods
Isolation of the Xenopus ANF gene and construction of
GFP transgenes
A 400-bp PstI fragment from the 5 terminus of the X.laevis
ANF coding region was used to probe a Xenopus Lambda
genomic library (courtesy of Mike King). Approximately 106
phage were screened at high stringency (0.2 SSC/0.1% SDS
at 65°C). Positive phage were purified and phage DNA was
isolated from liquid culture by cesium chloride gradient, re-
striction digested with EcoRI and subcloned for analysis. Re-
striction mapping and analysis by Southern blotting against the
5 region of the Xenopus ANF cDNA isolated an EcoRI frag-
ment that contains 3.4 kb of 5 flanking sequences.
For Xenopus transgenics, 3.4-kb and 625-bp fragments of
the ANF 5 regulatory sequences were amplified by using Pfu
polymerase and a 5 primer containing a SacI and EcoRI
linker, respectively: 5-TCCGGAGCTCGGCTGTCAGTCT-
CTGGATAA-3 and 5-GGAATTCCCAGTGAGCGATAT-
TTGC-3, and a 3 primer containing a BamHI linker: 5-
GTCTGTAAAGATATCACCGCCCTAGGGC-3.
Both the 3.4-kb and 625-bp regulatory sequences were
subcloned into the SacI/BamHI or EcoRI/BamHI sites, re-
spectively, of a modified pEGFP1 vector (Clontech).
The pEGFP-625ANF clone was used as a template for
site-directed mutagenesis using Pfu polymerase. The
pEGFP -NKE, -GATAp, -GATAd, -SREp, -SREd and -TBE
constructions were created by using the following oligonucle-
otides. Mutated regions are underlined NKE-SmaI: 5
TCCCCCGGGCTGCTCCGAAGGCGGGCTTCATTC-
CTCTGC-3 and 5-TCCCCCGGGGCATGATAAAGA-
ATCTGATTG-3; GATAp-ApaI: 5-GTGGGCCCC-
T T T A A A A G G G A A T C T T C T G - 3  a n d 5  -
GTGGGCCCTGCCCTCCACATTTCCACAG-3  ;
GATAd: 5-TGCTTTTACACCTGCATTCCTTATTAGT-3
and 5-GATGGGTCAGTTTATCCTTTTCAC; SREp: 5-
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TTATCCTGCCCTCCACATTTCCAC-3 and 5-
CAAGTGTATAGAATCTTCTGTTGGCCTTCAATCAGA-
3; SREd: 5-CCAAAGCTTTATTTAATAAATATGACG
and 5-TCAAACCCTCTGTTGGATTTACATTA-3; TBE:
5-TTCGGATGTAATGTGGAGGGCAGGAT-3; and 5-
TTTCCAGGAGGTGCCTTATCC-3.
Transgenesis
ANF promoter plus GFP reporter sequences were excised
from the plasmid vector by digestion with EcoRI/PmeI, and
the transgene was purified by using a QIAEX II gel extrac-
tion kit (Qiagen). The transgene was then used to generate
transgenic Xenopus embryos using previously described
protocols (Kroll and Amaya, 1996; Sparrow et al., 2000a).
Since greater than 90% of Xenopus embryos that are trans-
genic for one construction also coexpress a second construc-
tion (Huang et al., 1999; Marsh-Armstrong et al., 1999), -
crystallin–GFP expression in the eye was used as a control
transgene to assay for insertion of DNA into the genome
(Bronchian et al., 1999). Reporter gene expression was
detected by fluorescence in live embryos using a Leica Fl-II
microscope and MagnaFire digital camera or, in fixed em-
bryos, by whole-mount in situ hybridization for GFP tran-
scripts (Harland, 1991).
In presenting the results of transgenic experiments, we
are cautiously proposing a system in which activity of
different mutant promoters is expressed as a proportion of
wild type (wt) 625-bp ANF promoter activity. This seems
reasonable for the following reasons. First, examination of a
large number of transgenic embryos has established that
detectable expression of the GFP reporter is only observed
in 49% (90 of 184) of embryos transgenic for the wt ANF
promoter. Levels of GFP fluorescence vary widely among
the 49%, but it is likely that any promoter mutation that
reduces transgene expression will correspondingly increase
the proportion of embryos failing to reach the threshold of
detectable GFP fluorescence. Second, transgene expression
is likely to be influenced by several factors, including the
copy number of transgenes inserted, the relative head/tail
orientation of transgene insertions, and the effects of chro-
mosomal location. However, these effects will average out
for both wt and mutant promoters, providing that a sufficient
number of independent transgenic embryos are examined
for each construction. In order to discourage too much
emphasis on the precision of these estimates, relative pro-
moter activity have been stated to the nearest 5%.
Results
Conservation of transcription factor binding sites in the
mammalian and frog ANF promoters
In order to study the spatial and temporal regulation of
cardiac gene expression, we have isolated a 4.4-kb DNA
fragment containing the 5 flanking sequences of the Xeno-
pus atrial natriuretic factor (ANF) gene. Fig. 1 shows the
proximal promoter region of the Xenopus ANF gene to-
gether with an alignment of the sequence elements con-
served in the human ANF gene. The first 625 bp of 5
flanking sequences contains a number of transcription factor
binding sites, and both the sequence and the spacing of these
putative regulatory elements is highly conserved between
mammals and Xenopus. In particular, two SRF binding sites
(SRE), two GATA sites, a Tbx factor binding site (TBE),
and an NK2 factor binding site (NKE) are located within
350 bases of the start site of transcription. The proximal
SRE-like domain, which differs from a consensus SRE by 2
out of 10 bases, and the distal consensus SRE are identical
in the human and Xenopus genes. The Nkx2-5 binding
region (NKE) is 12 of 16 bp conserved between human and
Xenopus. The Xenopus 5 flanking region also contains the
proximal and distal GATA binding sites that are present in
the mammalian ANF promoters and a TBE, although this
last element is not precisely conserved in sequence or spac-
ing. Based on the high level of conservation of promoter
sequences, it seems likely that very similar regulatory mech-
anisms will be involved in controlling ANF transcription in
these evolutionarily divergent organisms.
Spatial and temporal regulation of the ANF promoter
During mammalian development, ANF is initially ex-
pressed in both the atrial and ventricular regions of the
myocardium of the developing heart (Zeller et al., 1987;
Habets et al., 2002). Later during development, ANF ex-
pression becomes limited to the atrial chambers of the heart,
with limited expression also observed in trabeculae of the
ventricle. In the rat, this restriction occurs at approximately
the time of birth (Zeller et al., 1987; Gardner et al., 1986;
Argentin et al., 1994). A very similar pattern of ANF ex-
pression is observed during frog cardiogenesis (Small and
Krieg, 2000), with ANF initially expressed throughout the
myocardium and in the developing outflow tract before
becoming restricted to the atrial chambers (Fig. 2A and B).
This restriction commences at approximately stage 47 of
development, corresponding to about 2 weeks after fertili-
zation (Fig. 2B). Unlike the mammalian expression pattern,
no expression of ANF is visible in the trabeculated ventric-
ular myocardium of the frog heart (Small and Krieg, 2000).
At no time is expression of ANF observed outside of the
heart.
In order to study the regulation of ANF transcription in
vivo, we have used the Xenopus transgenesis system (Kroll
and Amaya, 1996; Sparrow et al., 2000a). Preliminary ex-
periments compared the expression of a GFP reporter gene
in constructions containing either 3.4 kb or 625 bp of ANF
5 flanking sequence. Comparison of more than 20 individ-
ual transgenics for each construction showed that the ex-
pression levels and profiles were indistinguishable, and both
were identical to the expression profile of the endogenous
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ANF gene (data not shown). Based on these observations,
the shorter ANF promoter construction was used in all
subsequent studies. We have compared the pattern of ex-
pression of the wild type 625 bp ANF promoter-driven GFP
transgene with expression of the endogenous ANF gene
(Fig. 2). Transgene expression is first detected by fluores-
cence in the heart at approximately stage 34/35 (data not
shown). During subsequent development, the level of GFP
fluorescence increases and is prominent throughout both the
atrial and ventricular regions of the myocardium, as shown
in Fig. 2C–E. Expression of ANF in the atria always appears
much weaker than ventricular expression because the atrial
myocardial layer is only one or two cells across, whereas the
ventricular myocardium is very thick (Small and Krieg,
2000). Starting at approximately stage 47, GFP fluorescence
in the ventricle and the outflow tract begins to decrease and
expression becomes completely restricted to the atria at
about stage 49 (Fig. 2F and H). This restriction of ANF
expression to the atria occurs over a period of approxi-
mately 5 days under standard growth temperature condi-
tions (22°C). Observations using GFP fluorescence as the
reporter can be directly confirmed by in situ hybridization
Fig. 1. The 5 regulatory sequence of the Xenopus ANF promoter. The sequence of elements conserved in the human ANF promoter is aligned beneath the
corresponding frog sequence. The promoter contains an extended Nkx2-5 binding site (NKE) that is identical in 12 of 16 bases. Also conserved are a proximal
GATA (GATAp), distal GATA (GATAd), and two SRF binding sites (SREs) termed the proximal SRE (SREp) and distal SRE (SREd). The SREp and SREd
are both identical in the human and frog sequences. In addition to the primary sequence, the relative spacing of these binding sites is also highly conserved
between the frog and human promoters. Finally, the frog sequence contains a single Tbx binding site (TBE) that is not conserved in location compared with
the human promoter.
Fig. 2. The 625-bp wild-type Xenopus ANF promoter fragment recapitulates the endogenous ANF expression pattern. (A) In situ hybridization analysis of
stage 45 nontransgenic heart showing ANF expression throughout the atrium, ventricle, and outflow tract. (B) Stage 49 nontransgenic Xenopus heart showing
restriction of ANF transcripts to the atrial myocardium. (C) Stage 44 transgenic embryo showing GFP reporter expression driven by the wild-type 625-bp
ANF promoter. This is a ventrolateral view of a living embryo under combined UV and visible light. GFP fluorescence can be observed in the eye, driven
from the control -crystallin promoter and throughout the heart. (D) Fluorescent image of embryo in (C), highlighting GFP reporter expression. (E) Heart
of living stage 44 transgenic embryo, with GFP expression driven from the wild-type 625-bp ANF promoter. Fluorescence is visible throughout the atrium,
ventricle, and outflow tract. (F) Fluorescent image of dissected stage 48 transgenic heart, showing that GFP reporter expression is now limited to the atria.
(G) In situ hybridization analysis of dissected stage 45 transgenic heart, showing distribution of GFP transcripts throughout the heart. (H) In situ hybridization
analysis of GFP transcripts in dissected stage 49 transgenic heart. Note restriction of transgene expression to the atria, confirming the expression pattern
observed using fluorescence. Abbreviations: o, outflow tract; a, atria; v, ventricle.
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against GFP mRNA sequences (Fig. 2G and H), indicating
that the transgene expression pattern is not being misrepre-
sented due to GFP protein stability or different transparency
of the ventricular or atrial myocardial tissues. Finally, we
note that reporter gene expression from the wild type
625-bp ANF promoter is restricted to the heart at all stages
Fig. 3. Mutational analysis of the Xenopus ANF promoter in transgenic embryos. The different ANF promoter constructions are illustrated at the left of the
figure. Numbers on the top line indicate the distance of the regulatory element upstream of the transcription start site. The number of independently generated
transgenic embryos is indicated in the first column and the relative activity of the mutant constructions (expressed to the nearest 5%) is presented in the second
column. This number is calculated as the proportion of mutant transgene embryos showing visible reporter expression relative to the number of wild type
transgene embryos showing reporter expression (see Materials and methods).
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of development, indicating that the tissue specificity of the
promoter has been retained. Overall, the results with the
Xenopus ANF promoter are consistent with previous trans-
genic experiments utilizing mammalian promoters (Field,
1988; Knowlton et al., 1995; Habets et al., 2002). These
studies showed that all sequences required for cardiac spe-
cific expression are located within approximately 600 bp
upstream of the transcription start site.
The presence of two SRF binding sites is required for
efficient expression of the ANF promoter
Using expression from the wild type 625-bp ANF pro-
moter as a reference, we have undertaken a mutational
analysis to determine the relative importance of the different
promoter regulatory elements in controlling the efficiency
and tissue specificity of ANF expression in transgenic em-
bryos. We commenced this analysis with mutations of the
SREs, which act as binding sites for SRF. Constructions
were prepared in which either the proximal SRE (SREp) or
the distal SRE (SREd) were mutated, while taking care to
maintain precise spacing between regulatory elements. Us-
ing GFP fluorescence as the readout, more than 20 indepen-
dent F0 transgenic embryos were analyzed for each con-
struction. As shown in Fig. 3, mutation of either the
proximal or distal SRE results in a dramatic reduction in
expression from the ANF promoter, to approximately 10%
of the level observed from the wild type promoter. Since the
SRE mutant promoters resulted in very weak transgene
expression levels, no information on the requirements of
these sites for temporal or spatial regulation of ANF expres-
sion was obtained by using our assay.
The TBE is essential for efficient expression of the ANF
promoter
Mutation of the single TBE completely eliminates de-
tectable GFP reporter expression during early myocardial
development. By stage 45, about 5 days after the normal
onset of expression, GFP became visible in the hearts of
30% of transgenic embryos, albeit at much reduced levels
relative to wild type (n  18; data not shown). Determina-
tion of atrial restriction in these mutants was not possible
due to the very low levels of GFP. Based on these results, it
appears that a functional TBE is essential for the correct
temporal activation of ANF expression and also for normal
efficiency of the promoter.
A functional Nkx2-5 binding site is required for
restriction of ANF expression to the atrium
The ANF promoter contains a conserved Nkx2-5 binding
site, the NKE, centered at approximately 110 bp upstream
of the transcriptional start site. The sequence and spacing of
this element, relative to other promoter motifs, is highly
conserved between the Xenopus and the human ANF pro-
moters. As shown in Fig. 3, mutation of the NKE results in
a surprisingly minor reduction of reporter gene activity in
transgenic frog embryos. Analysis of 95 independent trans-
genic embryos shows that elimination of the Nkx2-5 bind-
ing site reduces detection of GFP expressing embryos to
approximately 60% of wild type levels. Apart from this
reduction in promoter activity from the NKE mutant pro-
moter, the time of onset of cardiac GFP expression and the
initial distribution of GFP fluorescence throughout the atrial
and ventricular myocardium appears identical to the wild
type sequence (data not shown).
The most striking aspect of the NKE mutant transgenics
is the appearance of GFP reporter expression in non-cardiac
tissues of the embryo. Ectopic expression is observed in the
developing kidneys, facial muscles, and in a group of mus-
cles adjacent to the aortic arch arteries, but never at any
other location (Fig. 4). GFP expression outside of the heart
was never observed in transgenics carrying the wild type
promoter (n  184) and so it seems extremely unlikely that
this expression is due to copy number or position effects at
the integration site. In NKE mutant transgenics, expression
in developing facial muscles is first detected at approxi-
mately stage 32 by visible fluorescence (Fig. 4A) and by in
situ hybridization (Fig. 4B). This is earlier than expression
in the heart, which is first detected at about stage 34. Later
in development, when muscle morphology is more pro-
nounced, it is possible to identify the facial muscles as the
musculus interhyoideus, musculus quadratohyangularis, and
orbitohyoideus (Sokol, 1977) (Fig. 4C–E). Ectopic trans-
gene expression is also observed in the interbranchialis I
and II, adjacent to the third and fourth aortic arch arteries,
and the subarcualis obliquus (Fig. 4C and D). Ectopic ex-
pression from the NKE mutant promoter also occurs in the
kidneys, as shown by fluorescence in a stage 44 embryo
(Fig. 4F).
Significantly, the NKE mutant also shows aberrant ex-
pression of the GFP reporter during later stages of heart
development. As described above, expression from the wild
type transgene becomes completely restricted to the atrial
myocardium by stage 49 of development, identical to ex-
pression of the endogenous ANF gene (Fig. 5A and B). In
the case of the NKE mutant, GFP fluorescence persists in
the outflow tract and is maintained at high levels in the
ventricular myocardium (Fig. 5C). The ventricular expres-
sion has never been observed to decrease in the NKE mu-
tants and persists for at least 3 weeks after expression is
restricted to the atria in wild type controls (Fig. 5B). Failure
of restriction was confirmed by in situ hybridization against
GFP mRNA (data not shown).
The distal GATA site is required for basal promoter
activity while the proximal GATA site is required for
restriction of ANF expression to the atrium
The ANF promoter contains two conserved GATA
sites at 160 and 293 designated proximal GATA
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(GATAp) and distal GATA (GATAd), respectively, in
Fig. 1. To examine the requirement of these elements for
ANF promoter function in vivo, we have generated pro-
moter constructions containing mutations of either the
GATAp, or GATAd alone, or mutations in both elements.
Once again, the mutations have preserved the correct
spacing of these elements relative to other regulatory
sequences. The results of our transgene experiments in-
dicate that the GATAp and GATAd sites have distinct
functions in the regulation of ANF promoter activity in
the frog embryo (Fig. 3). First, the distal GATA site
appears to be required for efficient expression from the
ANF promoter. Mutations in the GATAd element
strongly reduce expression of the GFP transgene, to
about 10% of wild type levels. This is approximately
equivalent to the degree of reduction observed when
either SRE was mutated. In all cases where GFP fluores-
cence was visible, expression from the GATAd mutant
promoter was limited to the developing heart. On the
other hand, the proximal GATA site appears to be in-
volved in regulation of tissue-specific expression of ANF.
Mutation of GATAp reduced detectable GFP expression
to approximately 30% of wild type numbers. Unlike
GATAd mutant expression, mutations in the GATAp
element resulted in ectopic expression of the GFP re-
porter in a subset of tissues apparently identical to those
observed for the NKE mutant. Furthermore, initial ex-
pression of the GATAp mutant in the heart appeared
normal, but GFP fluorescence failed to restrict to the atria
after stage 47 (Fig. 5D). Again, this is indistinguishable
from the expression observed with the NKE mutant pro-
moter. Finally, as might be expected, mutation of both
the proximal and distal GATA sites resulted in a com-
plete absence of detectable GFP transgene expression.
Overall, these results indicate that the proximal and distal
GATA sites are both required for efficient ANF expres-
sion, but that the proximal GATA element is also re-
quired for regulation of correct spatial expression.
Since mutation of either the proximal GATA site or
the NKE, individually, does not abolish the GFP trans-
gene expression, we have tested the activity of a con-
struction containing a double mutation of the NKE and
GATAp sites. Surprisingly, embryos transgenic for the
NKE and pGATA double mutant promoter still exhibit a
relatively high level of GFP transgene expression. As
shown in Fig. 3, expression from the NKE/GATAp dou-
ble mutant promoter is observed at approximately 45%
the frequency of the wild type control. Note that this is
similar to the expression levels observed for either the
NKE or the GATAp single mutations. Similarly, the
cardiac and ectopic expression pattern of GFP fluores-
cence driven by the NKE/GATAp double mutant is in-
distinguishable from that previously observed for the
NKE or GATAp single mutants (data not shown).
Discussion
Mutation of SRF binding sites in the ANF promoter
Our first transgenesis experiments focused on the con-
served SRF binding sites (SREs) in the ANF promoter, since
previous studies have suggested that these elements play a
central role in muscle gene regulation (Hines et al., 1999;
Wang et al., 2001a). Although the proximal SRE is not a
perfect consensus site, previous studies have shown that
both the proximal and distal SREs are capable of binding
SRF protein. Furthermore, although SRF binds the noncon-
sensus SREp with slightly lower affinity, functional analy-
ses have demonstrated that this site is indeed SRF-inducible
in cardiac myocytes (Hines et al., 1999). Our transgenic
studies showed that mutation of either the proximal or the
distal SRE resulted in a severe reduction in expression from
the ANF promoter, to about 10% of normal levels. These
observations are in complete agreement with a model in
which SRF proteins form the foundation of a transcription
complex containing myocardin, a powerful transcriptional
activator that does not itself possess DNA binding activity
(Wang et al., 2001a). Cell culture experiments using several
different cardiac-expressed promoters demonstrate that two
SRF binding sites are required for optimal activation by
myocardin (Wang et al., 2001a). With specific reference to
activity of the ANF promoter, however, our results disagree
with a previous study using ANF promoter constructions in
transfected primary cardiac muscle cells, which suggested
that the proximal SRE element played only a minor role in
basal promoter efficiency (Hines et al., 1999). These differ-
ences may reflect species specific variation in the impor-
tance of the proximal SRE between mammals and frogs, or
may be due to differences between the in vitro and trans-
genic assays.
A functional Tbx binding site is essential for correct ANF
expression
The mammalian ANF promoters contain three potential
TBEs. Although the sequence and location of the single
TBE in the Xenopus ANF promoter is not conserved with
any of those in the mammalian promoters, our results dem-
onstrate an important role for both the timing and efficiency
of ANF promoter activity. Mutation of the TBE results in
total absence of detectable GFP in the hearts of transgenic
embryos at the normal time of activation. Approximately 5
days later, GFP reporter expression becomes detectable in
about one-quarter of the transgenics, but at very low levels.
These results suggest that a functional TBE is essential for
regulation of both the time of activation and the efficiency
of expression of the ANF promoter. This finding is consis-
tent with previous studies showing that Tbx5 potently acti-
vates the ANF promoter in CV1 cells (Bruneau et al., 2001).
Furthermore, levels of Tbx5 seem to be crucial for ANF
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Fig. 4. Mutation of the NKE within the ANF promoter results in ectopic transgene expression outside of the heart. All transgenic embryos shown are mutant
for the NKE, but identical results are observed for the GATAp mutant promoter. (A) Fluorescent image of a living stage 32 transgenic embryo. Ectopic
expression of reporter GFP is visible in the developing facial muscles (indicated by an arrow head). Expression in the brain, from the control  crystallin
promoter, as indicated by an arrow. Apparent fluorescence in the flank of the embryo is background due to autofluorescence of yolk granules. Cardiac
expression of the transgene has not commenced at this stage. (B) In situ hybridization detection of GFP reporter gene expression in stage 32 embryo also
shows transcripts in developing facial muscles (arrowhead). (C) Combined brightfield and UV image of stage 45 transgenic embryo. Ventrolateral view shows
ectopic reporter expression in facial muscles and muscles associated with the third and fourth aortic arch artery. (D) Fluorescent image of the tadpole in (C)
showing ectopic GFP expression in the interbranchialis I and II (ib1 and ib2) adjacent to the third and forth aortic arch arteries, the subarcualis obliquus (so)
muscle, and the orbitohyoideus (or) muscle. Expression is also observed in the kidneys (ki). Transgene expression is strong in the heart (arrow). (E) Ventral
view of the head of a different transgenic embryo shows additional facial muscles expressing GFP. The orbitohyoideus (or) associated with the musculus
quadratohyangularis (qha) and the musculus interhyoideus (ih) are indicated. Control -crystallin promoter-driven GFP is observed in the eye. (F)
Dorsal-view of stage 45 transgenic embryo showing ectopic GFP expression in the kidneys (ki).
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expression. Mice heterozygous for Tbx5 show reduced lev-
els of ANF transcripts, while Tbx5 null mice completely
lack ANF expression (Bruneau et al., 2001). Other studies in
mice have reported that Tbx2 is able to cooperate with
Nkx2-5 to inhibit AV canal expression of ANF. This is
believed to be mediated via the TBE at 259, which is
adjacent to an NKE (Habets et al., 2002). This pairing of a
TBE and NKE is not present in the Xenopus ANF promoter.
Fig. 5. Mutations of the NKE or proximal GATA (GATAp) element within the ANF promoter result in persistent transgene expression throughout the ventricle and
outflow tract. (A) In situ hybridization analysis of dissected nontransgenic stage 49 heart, showing restriction of endogenous ANF transcripts to the atrium. Note
patchy expression of endogenous gene. (B) Fluorescent image of GFP expression in dissected stage 49 heart transgenic for the wild-type ANF promoter. Reporter
expression is restricted to atria and also shows patchy expression. (C) Fluorescent image of dissected stage 52 transgenic heart. Mutation of the NKE within the ANF
promoter results in persistent expression of the GFP reporter throughout the ventricle, and outflow tract. This ectopic expression persists for at least 3 weeks after
expression of endogeneous ANF, or the wild-type ANF transgene, has restricted to the atria. (D) Fluorescent image of GATAp mutant transgene expression in the
heart of a living stage 50 embryo. Expression is visible throughout the ventricle and outflow tract, exactly as observed with the NKE mutant transgene.
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Mutation of the NKE causes only a slight reduction in
ANF promoter activity
The sequence of the single NKE element is almost iden-
tical in the Xenopus and mammalian ANF promoters, sug-
gesting that the regulatory function of this element has been
conserved in evolutionarily distant organisms. In transgenic
Xenopus embryos, mutation of the NKE resulted in only a
relatively minor reduction in the number of embryos ex-
pressing GFP in the heart, to approximately 60% of wild
type levels. This result was initially very surprising, because
it appears to contradict the observation that ANF expression
is greatly reduced or completely absent in the Nkx2-5
knockout mouse (Harvey et al., 1999; Tanaka et al., 1999).
One explanation might be that, whereas Nkx2- 5 protein is
essential for ANF promoter activity, direct binding of the
protein to its target site is not. For example, it is possible
that protein–protein interactions with either GATA- 4 or
SRF are sufficient to tether Nkx2-5 to the transcription
complex, independent of direct binding to the NKE. This
interpretation is in general agreement with several in vitro
studies of the cardiac  actin and ANF promoters, which
have suggested that the absence of the NKE does not result
in a great reduction in promoter activity (Chen and
Schwartz, 1996; Durocher and Nemer, 1998). Indeed, a
nearly identical 50% reduction in promoter activity is ob-
served when an ANF promoter with a mutated NKE is
transiently transfected into primary cardiac myocytes (Du-
rocher and Nemer, 1998). Other experiments have shown
that the DNA binding domain of Nkx2-5 is not required for
activity of the cardiac  actin promoter, provided that SRF
is present (Chen and Schwartz, 1996). Together, these stud-
ies suggest that Nkx2-5 is indeed an important transcrip-
tional activator for ANF expression, but that direct interac-
tion of Nkx2-5 protein with DNA is largely dispensable. It
may not be appropriate to generalize this result too far,
however, since transgenic studies have shown that an
Nkx2-5 binding site is essential for GATA-6 promoter ac-
tivity (Molkentin et al., 2000). Overall, these transgenic and
cell culture studies suggest that the effect of NKE mutation
may be promoter-specific. In particular, the consequences
for transcriptional activity may be dependent on the pres-
ence of binding sites for specific cofactors that could form
a transcription complex with Nkx2- 5 and help to modulate
its activity. Finally, the most striking effect of NKE muta-
tion in transgenic embryos is activation of ANF promoter
activity in several different tissues outside of the developing
heart and the persistence of ANF expression in the ventricle
and outflow tract. These observations will be discussed
below.
Mutation of the GATA binding sites in the ANF promoter
Our transgenic studies indicate that the two GATA sites
in the ANF promoter exhibit distinct regulatory activities.
First, the distal GATA element is essential for efficient ANF
promoter activity, since mutants lacking this site showed
greatly reduced reporter gene expression (approximately
15% of wild type activity). This result is not consistent with
a previous cell culture study which suggested that the distal
GATA exerts only a modest effect on ANF promoter activ-
ity (Morin et al., 2001). On the other hand, the proximal
GATA element plays a more subtle role in modulating ANF
activity. Elimination of this site results in a moderate re-
duction in cardiac promoter activity, but also allows ectopic
expression of the GFP reporter in the facial muscles and in
the developing kidneys, apparently identical to the aberrant
pattern of expression observed for the NKE mutant. During
subsequent development of the heart, expression of the
proximal GATA mutant never restricted to the atria, again
corresponding to the pattern of the NKE mutant.
Mutation of both the proximal GATA and the NKE sites
Dual mutation of the proximal GATA site and the NKE
within the ANF promoter reduces reporter expression to
approximately half of wild type activity (Fig. 3). The ex-
pression of the double mutant is indistinguishable from both
the single NKE mutant, or the proximal GATA site mutant.
This result indicates that mutation of both binding sites
causes no further reduction in promoter activity or tissue
specificity than mutation of either site independently. These
results are in apparent disagreement with ANF promoter
studies in cultured cells, which suggest that binding of both
Nkx2-5 and GATA-4 is required for efficient transcription
(Lee et al., 1998). In fact, mutation of both the GATA and
NKE sites nearly eliminated promoter activity in primary
cardiac myocytes (Durocher and Nemer, 1998). Additional
cell culture studies indicated that GATA-4 and Nkx2-5
synergize strongly to activate ANF expression, resulting in
a transcriptional activation of between 25-fold and 200-fold
over expression levels observed with one of the factors
alone (Durocher et al., 1997; Lee et al., 1998). Our studies
in the transgenic embryo do not contradict a possible syn-
ergy between the Nkx2-5 and GATA proteins, but they
strongly suggest that the corresponding binding sites are not
required for this activation. Based on previous studies (Gru-
eneberg et al., 1992; Treisman, 1994; Chen and Schwartz,
1996; Belaguli et al., 2000), the most likely explanation is
that the SRF protein, binding to the essential proximal and
distal SRE sites, facilitates the assembly of a transcription
complex that includes both the GATA and Nkx2-5 proteins.
This would be similar to the proposed role for SRF in
providing a platform for recruitment of the non-DNA bind-
ing transcriptional activator, myocardin, to the promoter of
cardiac-specific genes (Wang et al., 2001a).
Tissue-specific regulation of ANF expression
An unexpected result of our transgene experiments was
the observation that mutation of either the NKE or the
proximal GATA element results in ectopic ANF promoter
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activity. In the wild type promoter, therefore, it appears that
the NKE and the proximal GATA can play an inhibitory
role, preventing ANF expression in ectopic tissues. Such an
inhibitory role for the NKE is consistent with previous
studies, suggesting that Nkx2-5, acting together with Tbx2,
inhibits ANF expression in the atrioventricular canal (AVC)
region of the mouse heart (Habets et al., 2002). We note,
however, that the NKE implicated in the AVC inhibition is
located at about 350 in the mouse ANF promoter and this
element is not conserved in the frog sequence. How might
the inhibitory function of the NKE be explained? Within
cardiac tissues, it is possible that Nkx2-5 undergoes a post-
translational modification that converts it from an activator
to a repressor of transcription (Fig. 6B). To explain the
observed pattern of ANF expression, the modification would
be limited to the ventricle and outflow tract tissues. A
necessary corollary of this model is that the posttransla-
tional modification would also prevent assembly of Nkx2-5
into the SRF transcription complex. If this were not the
case, then mutation of the NKE sequences would not have
any effect on ANF regulation in the transgenics. This model
has the advantage that the known interactions between
GATA and Nkx2-5 proteins (Durocher et al., 1997;
Sepulveda et al., 1998) may continue to be relevant for the
inhibitory mechanism.
An alternative explanation for these observations is that,
in kidney, facial muscles, and the ventricle, the NKE and/or
the GATA sites serve as the recognition sequence for a
distinct repressor protein (Fig. 6C). Activity of this putative
inhibitor in the ventricle and the outflow tract would result
in restriction of ANF expression in the atria. Mutation of the
inhibitor recognition sequence would be expected to prevent
inhibitor binding and thereby permit continued ANF tran-
scription. Since Nkx2-5 and GATA proteins continue to be
expressed throughout all myocardial tissues during devel-
opment and in the adult heart (Lints et al., 1993; Kasahara
et al., 1998; our unpublished observations), this model as-
sumes that the inhibitor would either displace Nkx2-5 from
the SRF-based transcription complex (Fig. 6C), or bind
directly to Nkx2-5 and completely inhibit its activation
properties (Fig. 6D). In general support of this model, Taki-
moto et al. (2000) have shown that persistent overexpres-
sion of Nkx2-5 throughout the myocardium increases ex-
pression of ANF in the ventricle after restriction, possibly by
competing with the inhibitor protein for NKE binding. Fur-
thermore, Durocher et al. (1996) showed that mutation of
the NKE caused an upregulation of ANF promoter activity
in ventricular myocytes, consistent with an inhibitory role in
this tissue.
Somewhat surprisingly, a relatively large number of pro-
teins capable of binding to the NKE have been reported, and
several of these may have the potential to act as inhibitors.
First, it appears that all members of the NK2 family of
homeodomain proteins, and also the NK3 (bagpipe) family
proteins, show affinity for a binding site closely related to
the 5-AAGTG-3 sequence present in the ANF NKE
(Guazzi et al., 1990; Okkema and Fire, 1994; Chen and
Schwartz, 1995; Carson et al., 2000; Steadman et al., 2000;
Sparrow et al., 2000b). All known NK2 proteins contain a
sequence N-terminal to the homeodomain that has similarity
to the engrailed repressor (Smith and Jaynes, 1996), al-
though there is currently no evidence that this domain
serves an inhibitory function in vivo. On the other hand, it
is clear that NK3 (bagpipe) family proteins may act as
transcriptional inhibitors (Steadman et al., 2000). Similarly,
it has been reported that the transcription factor COUP-TF1,
and homeodomain proteins of the Hmx family, can recog-
nize the Nkx2-5 binding site and may act as transcriptional
repressors by opposing the activity of Nkx2-5 (Amendt et
al., 1999; Guo et al., 2001). The expression patterns of most
of these potential inhibitors have not been reported during
the later stages of heart development, although the hmx1
orthologue in chicken, GH6, appears to be specifically ex-
pressed in the ventricular myocardium (Stadler and Solursh,
1994). Expression of the putative repressor may either be
restricted to nonatrial tissues, or alternatively, the factor
might undergo posttranslational modification to assume in-
hibitor activity in the nonatrial tissues. At present, it is not
possible to determine whether the same repressor that is
acting in the heart is also responsible for inhibiting ectopic
ANF expression in the facial muscles and kidney, or
whether different repressors are acting in the different tis-
sues.
The observation that mutation of the GATA and NKE
elements results in persistent expression of ANF in the
ventricle and outflow tract may help to more generally
illuminate the mechanisms by which atrial-specific expres-
sion of genes is achieved during normal development. In all
species examined, ANF is initially expressed throughout
developing atrial and ventricular myocardium and later be-
comes restricted to the atria (Zeller et al., 1987; Akizuki et
al., 1991; Seidman et al., 1991; Small and Krieg, 2000;
Houweling et al., 2002; Habets et al., 2002). Similarly, a
number of other atrial-specific genes, including the quail
Fig. 6. A model of ANF transcriptional regulation by Nkx2-5, GATA-4, and SRF. (A) In the early myocardium and in the mature atria activation of ANF
transcription is proposed to be regulated by a complex of Nkx2-5, SRF and cofactor myocardin, and GATA-4. (B) Inhibition of ANF transcription in the
ventricle may occur due to posttranslational modification of Nkx2-5, which results in exposure of an inhibitory domain within the protein. This modification
must also abolish Nkx2-5–SRF interactions since mutation of the Nkx2-5 binding site within the ANF promoter results in loss of inhibition in the ventricle.
(C) A second inhibitory model relies on a hypothetical repressor protein that becomes expressed (or activated) in the ventricle after stage 47. This repressor
protein would bind to the NKE and displace Nkx2-5 from the ANF promoter. (D) A third possible inhibitory mechanism results from the binding of a
ventricle-specific repressor protein directly to Nkx2-5. This interaction between Nkx2-5 and the candidate repressor must abolish the ability of Nkx2-5 to
interact with SRF, and therefore, to be tethered to the promoter in the absence of a functional NKE.
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slow MyHC3, mouse MLC2a and MLC1a (Wang et al.,
1996; Kubalak et al., 1994; Lyons, 1994), are initially ex-
pressed throughout the heart but later become limited to the
atrial chambers. In the case of slow MyHC3, atrial restric-
tion is proposed to require the inhibitory properties of the
homeodomain protein Irx4 (Wang et al., 2001b), which is
ventricle-specific in all species examined (Bao et al., 1999;
Bruneau et al., 2000; Garriock et al., 2001). The repression
of slow MyHC3 by Irx4 in the ventricle is thought to be
mediated by protein–protein interactions with a Vitamin
D–Retinoid X receptor complex. This complex tethers Irx4
to the vitamin D receptor binding element (VDRE) (Wang
et al., 2001b). Since the time of restriction to the atrium
varies widely between different cardiac genes, it is unlikely
that the same factors are involved in regulation of all atrial-
specific genes. However, we propose that inhibition by
chamber-specific factors is a general mechanism of restric-
tion of cardiac gene expression. The same families of in-
hibitory factors mentioned above might be considered as
candidates for the ventricular repressors involved in regu-
lation of other atrial-specific genes. In the case of the ho-
meodomain proteins, the inhibitors may interact with
GATA proteins to stabilize DNA binding.
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